|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Kate_Haviland
|
|
gptkbp:collaboratedWith
|
gptkb:Roche
gptkb:CStone_Pharmaceuticals
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
oncology
rare diseases
precision therapies
|
|
gptkbp:foundedIn
|
2011
|
|
gptkbp:founder
|
gptkb:Christopher_Varma
gptkb:Brian_Druker
gptkb:Nicholas_Lydon
gptkb:Alexis_Borisy
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Blueprint Medicines
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
gptkb:Ayvakit
gptkb:Gavreto
|
|
gptkbp:numberOfEmployees
|
over 400
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:receivedFDAApprovalFor
|
gptkb:Ayvakit
gptkb:Gavreto
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:BPMC
|
|
gptkbp:therapeuticArea
|
gptkb:non-small_cell_lung_cancer
gptkb:gastrointestinal_stromal_tumor
gptkb:systemic_mastocytosis
|
|
gptkbp:website
|
https://www.blueprintmedicines.com/
|
|
gptkbp:bfsParent
|
gptkb:Alexis_Borisy
gptkb:F-Prime_Capital
gptkb:Third_Rock_Ventures
gptkb:Atlas_Venture
gptkb:F-Prime_Capital_Partners
gptkb:pralsetinib
|
|
gptkbp:bfsLayer
|
6
|